Literature DB >> 11087565

Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors.

Q Han1, C Dominguez, P F Stouten, J M Park, D E Duffy, R A Galemmo, K A Rossi, R S Alexander, A M Smallwood, P C Wong, M M Wright, J M Luettgen, R M Knabb, R R Wexler.   

Abstract

Thrombotic diseases are a major cause of death and morbidity. Factor Xa (fXa) plays a vital role in the regulation of normal homeostasis and abnormal intravascular thrombus development in the blood coagulation cascade. A novel series of fXa inhibitors incorporating an amidino 6,5-fused bicyclic moiety at the P1 position has been designed and synthesized based on molecular modeling studies. Structure-activity relationship (SAR) studies have led to selective subnanomolar fXa inhibitors. The most potent fXa inhibitor in this series (72, SE170) has a potent inhibition constant (K(i) = 0.3 nM), is 350-fold selective for fXa over trypsin, and also shows good in vivo efficacy in a rabbit arterio-venous thrombosis model (ID(50) = 0.14 micromol/kg/h). An X-ray crystal structure of 72 complexed to bovine trypsin was completed, and a binding mode of 72 with fXa has been proposed based on modeling with human des-Gla-fXa.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11087565     DOI: 10.1021/jm000113t

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Design and Synthesis of TASIN Analogues Specifically Targeting Colorectal Cancer Cell Lines with Mutant Adenomatous Polyposis Coli (APC).

Authors:  Wentian Wang; Lu Zhang; Lorraine Morlock; Noelle S Williams; Jerry W Shay; Jef K De Brabander
Journal:  J Med Chem       Date:  2019-05-09       Impact factor: 7.446

2.  N-Phenacyldibromobenzimidazoles-Synthesis Optimization and Evaluation of Their Cytotoxic Activity.

Authors:  Anna Kowalkowska; Konrad Chojnacki; Maciej Multan; Jan K Maurin; Edyta Łukowska-Chojnacka; Patrycja Wińska
Journal:  Molecules       Date:  2022-07-07       Impact factor: 4.927

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.